We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
-17.97%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$115M
AUM Growth
-$50.3M
Cap. Flow
-$15.1M
Cap. Flow %
-13.13%
Top 10 Hldgs %
85.74%
Holding
24
New
3
Increased
3
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.5M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.45M
3
ONC
BeOne Medicines Ltd
ONC
+$1.44M
4
LRMR icon
Larimar Therapeutics
LRMR
+$399K
5
OCRX
Ocera Therapeutics, Inc.
OCRX
+$265K

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$21.7M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$151K
3
CTMX icon
CytomX Therapeutics
CTMX
+$150K

Sector Composition

Rank Sector Weight
1 Healthcare 67.13%
2 Miscellaneous 32.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$63M
$20.8M 18.07%
1,095,734
– –
CHRS icon
2
Coherus Oncology
CHRS
$226M
$13M 11.26%
611,010
– –
LPCN icon
3
Lipocine
LPCN
$18.4M
$8.63M 7.49%
49,995
– –
ANAC
4
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$7.52M 6.53%
140,756
– –
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$5.7M 4.95%
110,274
– –
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$5.52M 4.79%
500,000
– –
LRMR icon
7
Larimar Therapeutics
LRMR
$421M
$4.02M 3.49%
50,176
+5,053
+11% +$399K
OCRX
8
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.34M 2.03%
796,550
+92,820
+13% +$265K
AKTX
9
Akari Therapeutics
AKTX
$17.5M
$2.22M 1.92%
198
– –
SIOX
10
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.11M 1.84%
+23,014
New +$2.45M
ARCT icon
11
Arcturus Therapeutics
ARCT
$460M
$1.84M 1.59%
69,214
– –
ASND icon
12
Ascendis Pharma A/S
ASND
$16.4B
$1.67M 1.45%
90,000
– –
ORKA
13
Oruka Therapeutics
ORKA
$6.39B
$1.6M 1.39%
2,141
– –
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.52B
$1.59M 1.38%
+562,943
New +$2.5M
ONC
15
BeOne Medicines Ltd
ONC
$42.1B
$1.5M 1.3%
+51,000
New +$1.44M
PDSB icon
16
PDS Biotechnology
PDSB
$12.2M
$1.24M 1.07%
6,750
– –
GBT
17
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.16M 1.01%
72,990
+12,299
+20% +$219K
CTMX icon
18
CytomX Therapeutics
CTMX
$745M
$828K 0.72%
64,200
-10,800
-14% -$150K
STML
19
DELISTED
Stemline Therapeutics, Inc.
STML
$631K 0.55%
135,420
– –
RGNX icon
20
Regenxbio
RGNX
$619M
$567K 0.49%
52,500
– –
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$378K 0.33%
1,401
-474
-25% -$151K
GWPH
22
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-311,853
Closed -$21.7M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q1 2016 Portfolio in Review

As of Q1 2016, VHCP Management held 24 positions worth $115M, down 30% from $165M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

VHCP Management withdrew a net $15.1M in Q1 2016, closing 1 position and reducing 4 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $21.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Miscellaneous.

Against the trend, VHCP Management opened a new position in BioCryst Pharmaceuticals worth $1.59M.

  • VHCP Management's largest Q1 2016 buy was BioCryst Pharmaceuticals: 562,943 shares worth $1.59M.
  • VHCP Management added most to Larimar Therapeutics in Q1 2016, an estimated $399K increase.
  • VHCP Management's biggest Q1 2016 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $151K.
  • VHCP Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q1 2016, selling an estimated $21.7M.
  • VHCP Management's ten largest holdings make up 86% of its $115M portfolio in Q1 2016.
  • VHCP Management opened 3 new positions and closed 1 in Q1 2016.
  • VHCP Management's portfolio value fell 30% quarter-over-quarter to $115M.

Based on VHCP Management's 13F filing for Q1 2016, filed 13 May 2016.